Sales of antipsychotics and anticonvulsants in the Russian Federation for the period 2019—2024

Objective. To assess the structure and volume of consumption of antipsychotics, anticonvulsants and gabapentinoids in patients with neurotic disorders in the Russian Federation for the period 2019—2024. Material and methods. Data on sales of ATC class N05A (antipsychotics), N03A (anticonvulsants), and N02BF (gabapentinoids) according to current Russian clinical guidelines used in patients with neurotic, stress-related and somatoform disorders (ICD code F40-F48) in the period 2019—2024 were downloaded from the IQVIA database. Consumption data were taken into account for each INN in each year of follow-up in accordance with the defined daily doses (DDDs). The indicator “number of DDDs/1000 inhabitants per day” was calculated. Results. In 2019—2024, sales of antipsychotics in retail segment of the Russian Federation increased by 2 times (from 28.1 million DDDs in 2019 to 58.5 million DDDs in 2024) mainly due to atypical antipsychotics (quetiapine, olanzapine, risperidone). Estimated consumption increased from 1.08 DDDs/1.000 inhabitants per day in 2019 to 1.78 DDDs/1.000 inhabitants per day in 2024. There was a significant increase in sales of gabapentinoids (from 29 million DDDs in 2019 to 191 million DDDs in 2024) primarily due to multiple increase in sales of gabapentin. Sales of anticonvulsants in retail network increased slightly (from 77.1 million DDDs in 2019 to 83.7 DDDs in 2024). Conclusion. There are high risks of prescribing these classes of drugs off-label. Considering expansion of their prescriptions, it is necessary to conduct high-quality studies for assessing their effectiveness and safety, including patients with neurotic disorders.